RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+15.06%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1B
AUM Growth
+$1B
(+7.9%)
Cap. Flow
-$30M
Cap. Flow
% of AUM
-3%
Top 10 Holdings %
Top 10 Hldgs %
34.85%
Holding
100
New
15
Increased
28
Reduced
32
Closed
15
Top Buys
| 1 |
Medtronic
MDT
|
$17.8M |
| 2 |
Thermo Fisher Scientific
TMO
|
$17.5M |
| 3 |
Pfizer
PFE
|
$16.7M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$11.2M |
| 5 |
DexCom
DXCM
|
$8.07M |
Top Sells
| 1 |
Becton Dickinson
BDX
|
$24.6M |
| 2 |
CVS Health
CVS
|
$12.8M |
| 3 |
Eli Lilly
LLY
|
$12.8M |
| 4 |
Elevance Health
ELV
|
$11.8M |
| 5 |
McKesson
MCK
|
$11.6M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITCI
51
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.45M | 0.64% |
90,000
-5,000
| -5% | -$358K |
|
52
Axsome Therapeutics
AXSM
$6.09B
| $6.3M | 0.63% |
79,100
+39,000
| +97% | +$3.1M |
|
53
Immunovant
IMVT
$2.91B
| $6.15M | 0.61% |
146,061
-20,000
| -12% | -$843K |
|
|
54
Elevance Health
ELV
$72.4B
| $6.13M | 0.61% |
13,000
-25,000
| -66% | -$11.8M |
|
55
Apellis Pharmaceuticals
APLS
$3.51B
| $6.01M | 0.6% |
100,400
-114,600
| -53% | -$6.86M |
|
56
Immunocore
IMCR
$1.78B
| $5.76M | 0.58% |
84,278
-5,000
| -6% | -$342K |
|
57
Arvinas
ARVN
$580M
| $5.53M | 0.55% |
134,270
+49,270
| +58% | +$2.03M |
|
58
BridgeBio Pharma
BBIO
$9.91B
| $5.45M | 0.54% |
135,000
| – | – |
|
59
Madrigal Pharmaceuticals
MDGL
$9.7B
| $5.21M | 0.52% |
+22,500
| New | +$5.21M |
|
60
Xencor
XNCR
$594M
| $4.78M | 0.48% |
225,000
| – | – |
|
61
Relay Therapeutics
RLAY
$709M
| $4.29M | 0.43% |
390,000
+200,000
| +105% | +$2.2M |
|
|
RVNC
62
DELISTED
Revance Therapeutics, Inc.
RVNC
| $4.18M | 0.42% |
475,872
+114,193
| +32% | +$1M |
|
63
Insulet
PODD
$24.2B
| $4.12M | 0.41% |
+19,000
| New | +$4.12M |
|
64
Inspire Medical Systems
INSP
$2.53B
| $3.66M | 0.37% |
18,000
+11,000
| +157% | +$2.24M |
|
65
Labcorp
LH
$22.8B
| $3.41M | 0.34% |
+15,000
| New | +$3.41M |
|
66
Viking Therapeutics
VKTX
$3.02B
| $3.35M | 0.33% |
180,000
| – | – |
|
67
West Pharmaceutical
WST
$17.9B
| $3.17M | 0.32% |
9,000
| – | – |
|
68
Health Catalyst
HCAT
$228M
| $2.78M | 0.28% |
300,000
-20,000
| -6% | -$185K |
|
69
TG Therapeutics
TGTX
$5.03B
| $2.73M | 0.27% |
160,000
| – | – |
|
70
Lantheus
LNTH
$3.75B
| $2.48M | 0.25% |
40,000
-128,000
| -76% | -$7.94M |
|
71
NovoCure
NVCR
$1.35B
| $2.39M | 0.24% |
+160,000
| New | +$2.39M |
|
72
ESSA Pharma
EPIX
$11.2M
| $2.35M | 0.24% |
356,500
| – | – |
|
73
Pliant Therapeutics
PLRX
$105M
| $2.04M | 0.2% |
+112,741
| New | +$2.04M |
|
74
INmune Bio
INMB
$52.4M
| $2.01M | 0.2% |
178,284
| – | – |
|
75
Repligen
RGEN
$6.54B
| $1.8M | 0.18% |
+10,000
| New | +$1.8M |
|